Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions
Authors:
- 19 May 2015
- journal article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 16 (2) , 129-136
Abstract
We evaluated the cost-effectiveness of one-time pharmacogenomic testing for preventing adverse drug reactions (ADRs) over a patient's lifetime. We developed a Markov-based Monte Carlo microsimulation model to represent the ADR events in the lifetime of each patient. The base-case considered a 40-year-old patient. We measured health outcomes in life years (LYs) and quality-adjusted LYs (QALYs) and estimated costs using 2013 US$. In the base-case, one-time genetic testing had an incremental cost-effectiveness ratio (ICER) of $43,165 (95% confidence interval (CI) is ($42,769,$43,561)) per additional LY and $53,680 per additional QALY (95% CI is ($53,182,$54,179)), hence under the base-case one-time genetic testing is cost-effective. The ICER values were most sensitive to the average probability of death due to ADR, reduction in ADR rate due to genetic testing, mean ADR rate and cost of genetic testing.Keywords
This publication has 22 references indexed in Scilit:
- Emergency Hospitalizations for Adverse Drug Events in Older AmericansNew England Journal of Medicine, 2011
- Adverse Drug Events in U.S. Adult Ambulatory Medical CareHealth Services Research, 2011
- Adverse drug events in the outpatient setting: an 11‐year national analysisPharmacoepidemiology and Drug Safety, 2010
- The Case for Routine Genotyping in Dual-Antiplatelet TherapyJACC, 2010
- Warfarin Genotyping Reduces Hospitalization RatesJACC, 2010
- Markov Decision Processes: A Tool for Sequential Decision Making under UncertaintyMedical Decision Making, 2009
- When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D StudyNeuropsychopharmacology, 2009
- Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatmentThe Pharmacogenomics Journal, 2008
- A Composite Screening Tool for Medication Reviews of OutpatientsDrugs & Aging, 2007
- US Valuation of the EQ-5D Health StatesMedical Care, 2005